Kent Hawryluk has nearly 20 years’ experience as a life sciences entrepreneur, leader and investor. Mr. Hawryluk is President & CEO and one of our co-founders.
Mr. Hawryluk was a Co-founder and Chief Business Officer of Avidity Biosciences, a genetic medicines company, from January 2013 to December 2019. Under his leadership, Avidity raised $130 million in equity financings and initiated a significant strategic partnership with Eli Lilly. Previously, he served as Co-founder and CEO of MB2, a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Prior to MB2 and Avidity, Mr. Hawryluk co-founded Marcadia Biotech and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia, a pioneer in peptide multi-agonists of incretin receptors, was acquired by Roche in December 2010. Mr. Hawryluk served as a director of Gemphire Therapeutics, a public clinical-stage cardiovascular drug company, from February 2015 to February 2019. He has served as partner of Twilight Venture Partners, a private seed- and early-stage life science venture capital fund, since January 2003. Mr. Hawryluk holds a BA from Princeton University, an MBA from Kellogg School of Management at Northwestern University, and an MS, Biology from Purdue University.